At a Nordic leadership workshop a few years ago, Chelsea Ranger sat on a panel between the founders of Women in Life Science Denmark (WiLD) and VILDA, its Swedish counterpart. Surrounded by more than 200 experienced women in life sciences, she saw both the depth of talent in the room and the value of connecting that talent across borders. For Ranger, who had moved from the US and saw the Nordics as the region that had gotten equality right, it was a turning point. That night, she founded Women in Life Science Norway (Wild Norway). Their encouragement is a simple yet powerful message: “Because every ceiling reached becomes a new floor.”
WiLD Norway is a non-profit, professional network working for greater diversity and equity in Norway’s health and life sciences sector, to shift who leads, who gets funded, & what gets built across the value chain.
We discuss why women remain underrepresented in leadership despite dominating much of the healthcare workforce, why female-founded ventures continue to face funding disparities, and why this directly connects to women’s health as well as economic resilience and geopolitical preparedness.
WiLD Norway focuses on life sciences. Women already make up a large part of the workforce. How is that reflected in leadership?
My focus is life science because I’ve always been in the medical world. And we collaborate with a lot of other organisations that are working for women’s equality across every sector. These disparities are not unique to life science.
It’s not about getting more women into the field. on where in the hierarchy you look, we are up to 90 per cent of the workforce in some roles in healthcare. In leadership of private industry, however, we’re at 13 to 21 per cent represented. That is the same as what we see across male-dominated industries. So, we can dominate the work force; and that still does not mean that we dominate it’s leadership. We have run that experiment. That’s why mandates are still needed – they are the only measured areas where we start to see corporate leadership equity.

In life science, women are well represented throughout the talent pipeline; among medical students, PhD graduates and clinical trial staff. You would naturally expect to see more of that talent reflected in leadership as well.

Why do you think that happens?
I think it’s a natural extension of our collective history. We’ve lived with centuries of unstated societal quota that put men in leadership positions. Without mandates to make sure women are represented, I don’t think it changes on its own. We have to create an environment where women are placed in the right roles and given that opportunity. And companies and organizations should be held accountable when they don’t take that into consideration.
In our organization, we also work with men a lot. We have men on our board and in our member base and have since day one. I love environments where women get to be with women, and I think they’re important. But there’s a risk that we end up preaching to the choir about things we already know. When we involve men and get their investment in small changes with big impact in their personal and professional lives. That’s when things start to shift.

This has to be supported by policy all the way down. You have to look at where private funding, public research funding, and health care budgets are going, and ask whether you’re creating an environment that accounts for and funds women.
You have spent years helping to build health startups. Where are women founders heading today? Is it mainly femtech, or are more of them moving into tech and AI?
We are seeing more women go into tech and AI. It’s certainly not as many as we want or need, but there’s a lot more movement than there was even five years ago.
Women’s health and femtech are on a hockey-stick curve right now, with a lot of public and private funding going in at national, Nordic, and European levels. So a lot of women are moving in that direction, and statistically I think there will always be more women than men in that space. I would love to see more men get involved in women’s health and femtech, particularly from the private financing side.
Women are also prevalent in industry environments. But they’re often in clinical, medical, public affairs, and marketing roles – to a lesser degree in commercial roles and technical roles, and far too few in top leadership (national pharma GMs as perhaps the largest exception).
There is a well-known claim that the same idea pitched by a man is more likely to get funded than if a woman pitches it. Does the data support that?
It’s true, and there is evidence to back it up. I have numbers on Norway showing where the money goes for female-led teams and female CEOs compared with male-led teams. I believe Norway is actually the lowest in the Nordics for capital going into female-led teams.
A couple of years ago I went through a venture capital training camp, and they showed statistics on how men and women are received as founders. So I started teaching the startups I was working with this: when a man comes in and presents a case, investors ask about his likelihood of success. When a woman comes in with the same case, they ask about her likelihood of failure.
So in my view, a woman should always come in with a risk assessment. Here are the ways we could potentially fail, and here is how we’re mitigating each risk. You will be asked about it up front.
More women are working in venture capital now. Does that change which founders and ideas get funded?
It’s hard to generalise. More women are going into financing, but it’s still a heavily male-dominated environment. We do know that women investors are twice as likely to invest in women founders, and more likely to invest in female CEOs. So there is a statistical pattern of like following like.
At the same time, unconscious bias exists in women as well as men. It isn’t unique to men. We all have to look at where we might be biased and hold ourselves accountable.
With women’s health, I think a big driver of bias is that we’ve been defining it wrong for a very long time. If you define it as something special to women that is only reproductive, fertility or gynaecological, it is seen as a niche. We are over 50% of the global population – so that would still be the world’s largest niche. But the definition there is wrong from the start.
Women’s health is anything that uniquely affects women, affects women differently from men, or disproportionately affects women. Alzheimer’s disease, where women are two-thirds of patients, is women’s health. Cardiovascular disease. Migraine. Autoimmune disease. These are also women’s health.
With the broader definition, the perspective on the capital side changes. Venture capital can no longer look at it and say, “We don’t have enough successful exits to point to,” or “That’s a niche area and small market size.” Suddenly you’ve uncovered the ghost markets in women’s health, and I think miscategorisation is a big driver of the bias we see.
Which countries are still more traditional in their approach, and which are more modern?
The most widely used global comparison is probably the World Economic Forum’s Global Gender Gap Index, and the Nordic countries are consistently in the top ten, with Denmark having been a bit lower for some years (parity, so due to paternity leave). Norway is third and has closed about 86 per cent of its gender gap. On a global scale, the Nordic countries are genuinely progressive.
But there’s a big risk when we assume we’ve ticked the box, because then we stop asking questions. A couple of years ago, Deloitte and the Danish think tank Kraka published a study on what determines career success in Denmark. They looked at whether you were an immigrant or the child of immigrants, your parents’ education, your socio-economic background, your own degree and the industry you chose. The biggest barrier of all was being a woman. Every other group could close the gap with the right education and career choices. Women couldn’t. Same degree, same industry, and still behind. That’s in one of the most progressive countries in the world. Being a woman was the one disadvantage no choice could fix.
In our own work, we’ve noticed that countries seen as the most progressive don’t always feel that way in practice. Does that match your experience?
A lot of it is branding. We have to acknowledge where we’re doing really well, but it’s risky to assume. I come from the US and we’ve all seen recent years with DEI and women’s righsts setbacks, so I feel happy to be here in Norway.
The data side is also catching up. McKinsey and the World Economic Forum publish several reports a year, and they’ve started doing focused country reports on leadership and women’s health statistics. This year they’ve already published one for Switzerland, and I think one for Germany is coming. They haven’t done one for the Nordics yet, and many of us are trying to push idea forward.
Looking ahead, what do you want to achieve?
If I could shift two things, the first would be to have women represented equally everywhere decisions are made and money is allocated. That means policy, research committees, public and private funding bodies, public and private industry, healthcare institutions and patient care. I want equal representation across the entire value chain.
The argument then has to be that we don’t only want equality for equality’s sake. It is the impact of what happens when we are there – how our lived experience shapes how decisions are made, and priorities are set, and that connects to a greater societal impact than what we have today. That’s what we have to be able to show people.
The second is public health. The World Economic Forum, together with the McKinsey Health Institute, showed that nine medical conditions account for over 50% of the women’s health gap today. They’re not all reproductive conditions. They include migraine and heart disease. They also built the Women’s Health Impact Tracking (WHIT) platform, which lets countries plug in their own numbers and see which conditions should be prioritized and what the economic cost of inaction is.
I’d love to see policymakers pay to get those numbers where we don’t have them. Get the data, plug it in, and then look at where we need to prioritise. Right now, we are barely funding hugely impactful areas because economic costs are measured in different frameworks and pathways, and are often therefore left unconnected.
Politicians in Norway are doing work, but many have to start with a central focus, because the work is so big. Right now the bucket is menopause and how it affects the workforce and productivity. That is completely valid and something we have to take into account. Women leave the workforce in large numbers twice in our lives, during the child-rearing years, which often coincides with the onset of perimenopause (in countries where we are having children in late 20s and early 40s) and again around menopause. That affects societal productivity. It also affects healthcare, because women are the main providers of healthcare, elderly care and childcare, so when we lose women from the system, we lose them twice and measure that loss once. The impact is huge.
But that’s one area among many. Alzheimer’s is increasing, and women are two-thirds of patients, as well as around 80 per cent of caregivers. Research has also linked caring for someone with Alzheimer’s to a higher risk of developing it. These things are connected. We need the numbers, and then we need to address each of them. So I want to focus on women’s health in its broader definition, and I want to put women where they should be.
That is ambitious. Are governments moving fast enough?
I do see movement. But at the pace we’re going, it’s going to take another 100 years. We need to go faster.
What is the single biggest thing that needs to change to speed that up?
Again, I think it comes down to how we define things. First, how we define women’s health, because that changes everything: how we research it, fund it and care for it, how we diagnose and treat it, and which medicines we develop.
Second, how we define women. You can think about all this as a productivity issue, but think about where we are geopolitically. Every country right now is focusing on preparedness. And women are not merely the recipiences of health care; we are the backbone of it. Women provide societal wellness.
What do you need when you’re going into a situation where you might potentially send men to war en masse? You need a stable home front. We are moving into a disproportionately older and less healthy society. If women are not supported in that, if you don’t have a healthy female population, you don’t have a stable home front. In that sense, we need to see women as infrastructure, economic resilience, and geopolitical stability.
War and gender equality are rarely discussed together, yet security now dominates both the media and political agendas. Has this argument started to reach decision-makers?
We have the SHE conference here in Oslo, which runs every year. SHE stands for Social Human Equity, so it’s not just a women’s conference.

I hosted a panel asking whether women’s health is Europe’s most overlooked growth strategy. We had a chief medical officer from our defence industry, along with clinicians, founders, and scientists. We discussed what geopolitical preparedness means, and why women’s health, expertise and participation matter to Europe’s resilience.
You’re right that people aren’t really talking about this yet. But if we made it a broader argument, I think we could see politicians shift their thinking. Preparedness is one of the core considerations for everybody right now.






